Compare TransMedics Group Inc (TMDX) vs United Microelectronics Corp (UMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TransMedics Group Inc vs United Microelectronics Corp — how do they compare? TransMedics Group Inc trades at $85.89 (market cap $3.06B), while United Microelectronics Corp trades at $22.44 (market cap $54.48B). The key difference: United Microelectronics Corp is far larger — about 17.8× TransMedics Group Inc's market cap, and United Microelectronics Corp pays a 1.84% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| TMDX | UMC | |
|---|---|---|
Market Cap | $3.06B | $54.48B |
Sector | Technology | Technology |
52-Week High | $150.42 | $28.02 |
52-Week Low | $61.99 | $6.76 |
Enterprise Value | $3.46B | $51.52B |
Dividend Yield | — | 1.84% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TransMedics Group (TMDX) trades at $88.27, down 1.9% on the day, with a bullish technical signal from moving averages but mixed earnings results. The company reported strong revenue growth to $605.49M in 2025, with a net income margin of 22.69%, though profitability is expected to moderate in 2026. Recent news highlights ongoing legal investigations into fiduciary duties alongside positive coverage of growth initiatives in kidney transplantation and European expansion.
The stock presents a growth opportunity with analyst consensus pointing to a $99.57 price target, but risks include margin pressure from heavy investments and legal uncertainties. Earnings misses in recent quarters and a projected decline in net income for 2026 warrant caution, though institutional interest remains with a bullish rating from 69% of analysts.
UMC trades at $21.82, up 5.06% in 24 hours, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong Q2 2026 earnings, beating estimates with EPS of $0.54 versus $0.16 expected, and announced a $0.41 dividend payable in August 2026. Revenue trends show recovery, with 2026 projections at $250.7B and net income margin improving to 32.75%.
Outlook is positive due to earnings momentum and AI expansion plans, but risks include competitive pressures and volatility from AI spending concerns. Analyst consensus is mixed with 27% buy ratings, suggesting cautious optimism amid high valuation multiples like P/E of 20.96.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →About United Microelectronics Corp
Founded in 1980, United Microelectronics is the world's third-largest dedicated chip foundry, with 7% market share in 2021, according to Gartner, after TSMC and GlobalFoundries. UMC's headquarters are in Hsinchu, Taiwan, and it operates 12 fabs in Taiwan, Mainland China, Japan and Singapore, with additional sales offices in Europe, the U.S. and South Korea. UMC features a diverse customer base including Texas Instruments, MediaTek, Qualcomm, Broadcom, Xilinx and Realtek, supplying a wide range of products applied in communications, display, memory, automotive and more. UMC employs about 20,000 people.
Read more on UMC →
